Using stem cells to treat multiple system atrophy
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial of Intrathecally Administered Autologous Mesenchymal Stem Cells in Multiple System Atrophy
This study is looking at whether using your own stem cells, delivered into the spinal canal, can help slow down the progression of multiple system atrophy (MSA), and it's for people living with this challenging condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10872108 on NIH RePORTER |
What this research studies
This research investigates the use of autologous mesenchymal stem cells (MSCs) delivered directly into the spinal canal to treat multiple system atrophy (MSA), a severe neurodegenerative disease. The study aims to determine the effectiveness and safety of this treatment approach through a randomized, double-blind, placebo-controlled trial. Patients will receive either the stem cell treatment or a placebo, and their progress will be monitored over time to assess changes in disease progression and overall health. The research builds on previous findings that suggest MSCs may help slow the progression of MSA by increasing neurotrophic factors in the body.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with early-stage multiple system atrophy who are seeking potential new treatment options.
Not a fit: Patients with advanced multiple system atrophy or those who do not meet the eligibility criteria for the trial may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that slows the progression of multiple system atrophy and improves quality of life for patients.
How similar studies have performed: Previous studies have shown promising results with similar approaches using stem cells in neurodegenerative diseases, indicating potential for success in this trial.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Singer, Wolfgang — Mayo Clinic Rochester
- Study coordinator: Singer, Wolfgang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.